{"id":45449,"date":"2025-10-31T20:45:56","date_gmt":"2025-10-31T12:45:56","guid":{"rendered":"https:\/\/flcube.com\/?p=45449"},"modified":"2025-10-31T20:45:57","modified_gmt":"2025-10-31T12:45:57","slug":"chengdu-maxvax-secures-series-d-financing-at-over-rmb-400-million-to-accelerate-shingles-and-rsv-vaccine-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45449","title":{"rendered":"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development"},"content":{"rendered":"\n<p>China\u2011based <strong>Chengdu Maxvax Biotechnology Co., Ltd.<\/strong> announced the successful completion of its Series\u202fD funding round, raising <strong>over RMB\u202f400\u202fmillion<\/strong>. The round was led jointly by <strong>IDG Capital, Shenzhen Capital Group (SCGC)<\/strong> and <strong>Ruipu Pharma<\/strong>, underscoring confidence in Maxvax\u2019s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-capital-allocation-and-strategic-focus\">Capital Allocation and Strategic Focus<\/h3>\n\n\n\n<p>The newly raised capital will be directed toward:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program<\/th><th>Development Stage<\/th><th>Primary Objective<\/th><\/tr><\/thead><tbody><tr><td>Recombinant shingles (herpes\u202fzoster) vaccine<\/td><td><strong>Phase\u202fIII<\/strong><\/td><td>Commercial\u2010preparation and market entry.<\/td><\/tr><tr><td>Recombinant respiratory syncytial virus (RSV) vaccine<\/td><td><strong>Phase\u202fIII<\/strong><\/td><td>Global safety &amp; efficacy assessment.<\/td><\/tr><tr><td>Multiple innovative candidates<\/td><td><strong>Pre\u2011clinical<\/strong><\/td><td>Further research and international collaborative development.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Maxvax\u2019s commitment to public health is reflected in its plan to move from bench to bedside (and shelter) with a vertically integrated value chain that spans adjuvant R&amp;D, formulation, and delivery systems.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-corporate-position-and-capabilities\">Corporate Position and Capabilities<\/h3>\n\n\n\n<p>Maxvax Biotech\u2019s proprietary platform combines adjuvant chemistry, recombinant protein technology, and immune\u2011evaluation assays. The company has:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Developed <strong>\u224820 adjuvant raw materials<\/strong> and <strong>3 mature delivery systems<\/strong>.<\/li>\n\n\n\n<li>Created <strong>10+ composite formulations<\/strong> for both human and companion\u2011animal vaccines.<\/li>\n\n\n\n<li>Built an end\u2011to\u2011end value chain covering R&amp;D, manufacturing, formulation, and clinical deployment.<\/li>\n<\/ul>\n\n\n\n<p>With these assets, Maxvax is positioned to address both emerging infectious threats and chronic disease prevention on a global scale.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-investor-and-market-implications\">Investor and Market Implications<\/h3>\n\n\n\n<p>The Series\u202fD funding signals strong institutional support and positions Chengdu Maxvax to speed the delivery of its first two clinical candidate vaccines. Analysts will watch the company\u2019s RSV and shingles trials for early safety signals and market potential, while the integrated supply chain may offer a competitive edge in vaccine manufacturing and logistics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series\u202fD funding round,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45450,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,580,12],"class_list":["post-45449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-maxvax-biotechnology","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series\u202fD funding round, raising over RMB\u202f400\u202fmillion. The round was led jointly by IDG Capital, Shenzhen Capital Group (SCGC) and Ruipu Pharma, underscoring confidence in Maxvax\u2019s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45449\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series\u202fD funding round, raising over RMB\u202f400\u202fmillion. The round was led jointly by IDG Capital, Shenzhen Capital Group (SCGC) and Ruipu Pharma, underscoring confidence in Maxvax\u2019s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45449\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T12:45:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T12:45:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development\",\"datePublished\":\"2025-10-31T12:45:56+00:00\",\"dateModified\":\"2025-10-31T12:45:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101-1.webp\",\"keywords\":[\"Finance\",\"Maxvax Biotechnology\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45449#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45449\",\"name\":\"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101-1.webp\",\"datePublished\":\"2025-10-31T12:45:56+00:00\",\"dateModified\":\"2025-10-31T12:45:57+00:00\",\"description\":\"China\u2011based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series\u202fD funding round, raising over RMB\u202f400\u202fmillion. The round was led jointly by IDG Capital, Shenzhen Capital Group (SCGC) and Ruipu Pharma, underscoring confidence in Maxvax\u2019s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45449\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3101-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45449#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series\u202fD funding round, raising over RMB\u202f400\u202fmillion. The round was led jointly by IDG Capital, Shenzhen Capital Group (SCGC) and Ruipu Pharma, underscoring confidence in Maxvax\u2019s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45449","og_locale":"en_US","og_type":"article","og_title":"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development","og_description":"China\u2011based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series\u202fD funding round, raising over RMB\u202f400\u202fmillion. The round was led jointly by IDG Capital, Shenzhen Capital Group (SCGC) and Ruipu Pharma, underscoring confidence in Maxvax\u2019s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.","og_url":"https:\/\/flcube.com\/?p=45449","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T12:45:56+00:00","article_modified_time":"2025-10-31T12:45:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45449#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45449"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development","datePublished":"2025-10-31T12:45:56+00:00","dateModified":"2025-10-31T12:45:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45449"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45449#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101-1.webp","keywords":["Finance","Maxvax Biotechnology","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45449#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45449","url":"https:\/\/flcube.com\/?p=45449","name":"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45449#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45449#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101-1.webp","datePublished":"2025-10-31T12:45:56+00:00","dateModified":"2025-10-31T12:45:57+00:00","description":"China\u2011based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series\u202fD funding round, raising over RMB\u202f400\u202fmillion. The round was led jointly by IDG Capital, Shenzhen Capital Group (SCGC) and Ruipu Pharma, underscoring confidence in Maxvax\u2019s pipeline and the growing demand for recombinant protein vaccines in both human and veterinary markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45449#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45449"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45449#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101-1.webp","width":1080,"height":608,"caption":"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45449#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chengdu\u202fMaxvax Secures Series\u202fD Financing at Over RMB\u202f400\u202fMillion to Accelerate Shingles and RSV Vaccine Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3101-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45449"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45449\/revisions"}],"predecessor-version":[{"id":45451,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45449\/revisions\/45451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45450"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}